In a meta-analysis of eleven randomized clinical trials evaluating the effect of hyperoncotic colloids on AKI in a wide variety of clinical scenarios including ascites, surgery, sepsis and spontaneous bacterial peritonitis, Wiedermann et al. demonstrated that administration of hyperoncotic albumin solutions could decrease the odds of AKI by 76% [52]. The gene discussed is ALB; the disease is acute kidney injury.